Human Biostar revises stem cell laboratory
The lab, which was temporarily shut down for revision, has again resumed operations to serve stem cell banking customers. The GTP Centre I, which has been initially completed
The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S).
Somatoprim, the somatostatin analog (SSA) based on a novel amino acid composition, demonstrated significant receptor binding and pharmacological profile compared to currently marketed SSAs. Aspireo CEO Carsten Dehning